Johnson and Johnson Vision has released three-year data for Acuvue Abiliti 1Day soft therapeutic lenses for myopia management (Abiliti 1-Day).

The data provides further validation of Acuvue Abiliti 1Day’s efficacy as a myopia management tool, showing that 55.2% of children wearing Abiliti 1Day showed no clinically meaningful myopia progression* over threeyears,^1 and mean axial elongation was reduced by 0.31 mm, on average, over three-years.¥1

Acuvue Abiliti 1Day features novel RingBoost technology2 with non-coaxial optics – a deliberate departure from traditional multifocal/dual focus approaches. By creating myopic retinal defocus off the line of sight, the design includes two stronger treatment zones (+7D) plus a central boost (+10D) while maintaining visual quality.2 Clinical trial data show over 95% of children achieved 6/6 vision or better while wearing the lens,§3 addressing a key clinician concern: efficacy should not come at the cost of everyday visual function.

Abiliti 1Day is made from the same material (senofilcon A) as Acuvue Oasys 1-Day and its smaller diameter improves handling, insertion, and removal.†4

According to Johnson and Johnson Vision data on file, 90.8% of children reported they never or rarely could feel the lens on their eyes while wearing Abiliti 1-Day, 89.2% of children agreed the lens was easy to put in the eyes, and 93.8% agreed it was easy to take out of the eyes. Additionally, 95.4% reported they never or rarely experienced Abiliti 1-Day lens moving out of place or falling out.#5

References and footnotes available at mivision.com.au.